Mergers & Acquisitions
United Kingdom
29 August 2025
With global strength in life sciences, Latham & Watkins frequently advises lenders and investors in financing and funding rounds. The firm also draws on its regulatory expertise to assist a range of life sciences and healthcare clients with commercial agreements, collaboration and licensing transactions, as well as UK and EU compliance and privacy matters. The practice is led by Robbie McLaren, who is highly experienced in cross-border M&A and venture and growth capital investments. Melanie Howard, who joined from Baker McKenzie LLP in September 2024, further strengthens the team’s M&A, securities law, financing structures, and global carve-outs offering. Samantha Peacock is trusted for corporate matters, including M&A, VC investments, and reorganisations.
Legal 500 Editorial commentary
Accolades
Client satisfaction
Key clients
- atai Life Sciences
- BC Partners
- Canaan
- Brandon Capital
- Intuitive Ventures
- Octopus Ventures
- Redalpine Capital
- Novo Holdings
- Stevanato Group S.p.A.
- Synthomer
- B-Flexion
- SKKY Partners
Work highlights
Advised BC Partners, an international investment firm, on its agreement with Goldman Sachs Alternatives, under which the private equity business at Goldman Sachs Alternatives will acquire a majority stake in Synthon, an international pharmaceutical company, from funds advised by BC Partners.
Advised Novo Holdings as the co-lead investor in the Series E Preferred Stock financing round for Quanta Dialysis Technologies.
Advised Intuitive Ventures on its participation in the US$100 million Series A funding round of Amber Therapeutics, a London-based med tech company developing breakthrough adaptive neuromodulation therapy to treat mixed urinary incontinence.
Practice head
Robbie McLaren
Other key lawyers
Melanie Howard; Samantha Peacock; Jenna Gascoyne